Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Short term Debt (2023 - 2025)

Historic Short term Debt for Spyre Therapeutics (SYRE) over the last 3 years, with Q3 2025 value amounting to $11.0 million.

  • Spyre Therapeutics' Short term Debt fell 5545.68% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 5545.68%. This contributed to the annual value of $25.1 million for FY2024, which is 170431.65% up from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Short term Debt is $11.0 million, which was down 5545.68% from $59.9 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Short term Debt high stood at $164.4 million for Q2 2023, and its period low was $1.4 million during Q4 2023.
  • For the 3-year period, Spyre Therapeutics' Short term Debt averaged around $34.2 million, with its median value being $17.9 million (2024).
  • Its Short term Debt has fluctuated over the past 5 years, first tumbled by 9839.4% in 2024, then skyrocketed by 216893.94% in 2025.
  • Spyre Therapeutics' Short term Debt (Quarter) stood at $1.4 million in 2023, then soared by 1704.32% to $25.1 million in 2024, then tumbled by 56.06% to $11.0 million in 2025.
  • Its Short term Debt was $11.0 million in Q3 2025, compared to $59.9 million in Q2 2025 and $42.8 million in Q1 2025.